Abstract
The challenges of developing drugs for central nervous system disorders have led some major companies to reduce or discontinue investment in the field, even though the unmet medical need is substantial. How can the wealth of basic research knowledge in neuroscience be successfully translated into new therapies?
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on SpringerLink
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Author information
Authors and Affiliations
Ethics declarations
Competing interests
Darryle D. Schoepp is employed by Merck and Co., Inc., USA.
Rights and permissions
About this article
Cite this article
Schoepp, D. Where will new neuroscience therapies come from?. Nat Rev Drug Discov 10, 715–716 (2011). https://doi.org/10.1038/nrd3559
Published:
Issue date:
DOI: https://doi.org/10.1038/nrd3559
This article is cited by
-
Allosteric ligands for the pharmacologically dark receptors GPR68 and GPR65
Nature (2015)
-
Mining mouse behavior for patterns predicting psychiatric drug classification
Psychopharmacology (2014)
-
A safe lithium mimetic for bipolar disorder
Nature Communications (2013)
-
Quantitative systems pharmacology as an extension of PK/PD modeling in CNS research and development
Journal of Pharmacokinetics and Pharmacodynamics (2013)
